ResearcherCornell UniversityActive in the last 2 years
Rohit Chandwani
Matched on ORCID iD 0000-0003-4781-6069; OpenAlex author ID A5038333017. Sources: funder_awards.
Their work
- Papers
- 7 (first author 0, last author 2)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 38
2016: 1 grant · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper, 1 grant · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 2 papers
Papers 7
- Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. Co-author DOI 10.1016/j.devcel.2026.04.012↗
- Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1245/s10434-026-19546-9↗
- Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Last author DOI 10.1016/j.ccell.2024.08.002↗
- A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Co-author DOI 10.1016/j.stem.2023.11.011↗
- Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer. Last author DOI 10.1016/j.jcmgh.2021.07.014↗
- Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
- Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1920240117↗
Grants 2
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Steven D Leach · 5 shared papers, 2020–2026 · strength 0.84
- Paper Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer. DOI 10.1016/j.jcmgh.2021.07.014↗
- Paper Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. DOI 10.1016/j.devcel.2026.04.012↗
- Paper A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. DOI 10.1016/j.stem.2023.11.011↗
- Adrien Grimont · 3 shared papers, 2022–2026 · strength 0.61
- Paper Uncertain Beginnings: Acinar and Ductal Cell Plasticity in the Development of Pancreatic Cancer. DOI 10.1016/j.jcmgh.2021.07.014↗
- Paper Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. DOI 10.1016/j.devcel.2026.04.012↗
- Paper Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. DOI 10.1016/j.ccell.2024.08.002↗
- Gökçe Aşkan · 3 shared papers, 2020–2026 · strength 0.39
- Paper Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. DOI 10.1016/j.devcel.2026.04.012↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Christine A. Iacobuzio–Donahue · 3 shared papers, 2020–2026 · strength 0.39
- Paper Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformation. DOI 10.1016/j.devcel.2026.04.012↗
- Paper Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreati… DOI 10.1073/pnas.1920240117↗
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Fong Cheng Pan · 2 shared papers, 2024–2026 · strength 0.39
- Jean Closset · 1 shared paper, 2026 · strength 0.24
- D. Nageshwar Reddy · 1 shared paper, 2026 · strength 0.24
- James Lau · 1 shared paper, 2026 · strength 0.24
- Kazuhiko Kasuya · 1 shared paper, 2026 · strength 0.24
- Sergio Alfieri · 1 shared paper, 2026 · strength 0.24
- Guido Costamagna · 1 shared paper, 2026 · strength 0.24
- Takao Itoi · 1 shared paper, 2026 · strength 0.24
- Aslihan Yavas · 1 shared paper, 2026 · strength 0.20
- Xian Zhang · 1 shared paper, 2026 · strength 0.20
- Danwei Huangfu · 1 shared paper, 2026 · strength 0.20
- Jen Jen Yeh · 1 shared paper, 2026 · strength 0.20
- Xiaohua Duan · 1 shared paper, 2024 · strength 0.18
- Alessandra Pulvirenti · 1 shared paper, 2024 · strength 0.14
- Caitlin A. McIntyre · 1 shared paper, 2024 · strength 0.14
- Wungki Park · 1 shared paper, 2024 · strength 0.14
- Eileen Mary O'Reilly · 1 shared paper, 2024 · strength 0.14
- Despina Siolas · 1 shared paper, 2024 · strength 0.14
- William R. Jarnagin · 1 shared paper, 2024 · strength 0.14
- Brett Logan Ecker · 1 shared paper, 2024 · strength 0.14
- Faiyaz Notta · 1 shared paper, 2024 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.